2751. Cefiderocol Use in Treating Patients with Confirmed Stenotrophomonas maltophilia Infections in US Hospitals During January 2020 - June 2022
Open Forum Infectious Diseases · 27.11.2023 · 10 (Supplement_2)
DOI: 10.1093/ofid/ofad500.2362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 27.11.2023. Verfasst von Bin Cai und 4 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Stenotrophomonas maltophilia (SM) infections have been associated with high mortality rates (21% to 69%), particularly in critically ill patients because of SM inherent resistance to many antibiotics, including carbapenems. This study describes cefiderocol (CFDC) treating hospitalized patients infected with SM in the US.
Methods
This retrospective observational study used January 2020-June 22 Premier Healthcare Database. Inclusion criteria are age ≥18 years, non-COVID, a positive SM culture without other Gram-negative pathogens identified within ±3 days and received CFDC ≥3 days on or after first SM culture. This study describes the patient characteristics, cefiderocol use pattern, and overall, 14-day and 28-day in-hospital all-cause mortalities (IHACM) with 95% confidence intervals (CI). First SM culture is the Index culture.
Results
Of 19 patients meeting the inclusion criteria, median age was 62 years with an interquartile range (IQR) of 56-76 years, 57.9% were male, 63.2% came from home, and 89.5% were admitted via emergency room or urgent care. Top comorbidities at admission were renal disease (68.4%), congestive heart failure (52.6%), chronic pulmonary disease (31.6%), and peripheral vascular disease (31.6%). Over 68% of patients were in the ICU, with the same rate of receiving both mechanical ventilation and vasopressor support at the time of index culture. Also 68.4% of index cultures were from respiratory and 10.5% from blood. CFDC was initiated ≤5 days of index culture in 8 (42.1%) patients, 6-20 days in 9 (47.4%) patients, and >20 days in 2 (10.5%) patients. Median days on CFDC was 8 days (IQR: 4-12), longer for patients who started CFDC later. All 19 patients received other antibiotics prior to CFDC. Twelve (63.2%) patients received other antibiotics during CFDC treatment, and the most common antibiotics were levofloxacin (50.0%), eravacycline (50.0%), cefepime (33.3%), or minocycline (33.3%). Median of hospital stays after index culture was 18 days (IRQ:8-30). Crude overall IHACM was 36.8% (95%CI: 15.8%-58.5%). Crude 28-day IHACM from index culture was 21.1% (95%CI: 2.7%-39.4%).
Conclusion
SM is a rare Gram-negative pathogen with limited treatment options. CFDC offers an additional treatment option against this pathogen. Further investigation is warranted. Disclosures Bin Cai, MD, PhD, Shionogi Inc.: Shionogi employee Sean T. Nguyen, PharmD, Shionogi: Employee|Shionogi, Inc: Employee Jennifer D. copeland, MS, Shionogi, Inc.: Employee (Medical/Micro) Christine M. Slover, PharmD, Shionogi,INC: Employee
Zitieren
APA
Cai, B., Nguyen, S. T., Copeland, J. D., Song, H. J., & Slover, C. M. (2023). 2751. Cefiderocol Use in Treating Patients with Confirmed Stenotrophomonas maltophilia Infections in US Hospitals During January 2020 - June 2022. Open Forum Infectious Diseases, 10(Supplement_2). https://doi.org/10.1093/ofid/ofad500.2362
Vancouver
Cai B, Nguyen ST, Copeland JD, Song HJ, Slover CM. 2751. Cefiderocol Use in Treating Patients with Confirmed Stenotrophomonas maltophilia Infections in US Hospitals During January 2020 - June 2022. Open Forum Infectious Diseases. 2023;10(Supplement_2). doi:10.1093/ofid/ofad500.2362
BibTeX
@article{Cai2023,
author = {Cai, Bin and Nguyen, Sean T and Copeland, Jennifer D and Song, Hyun Jin and Slover, Christine M},
title = {2751. Cefiderocol Use in Treating Patients with Confirmed Stenotrophomonas maltophilia Infections in US Hospitals During January 2020 - June 2022},
journal = {Open Forum Infectious Diseases},
year = {2023},
volume = {10},
number = {Supplement_2},
doi = {10.1093/ofid/ofad500.2362}
}
EUVIMED